Global Hemophilia A Therapeutics Market 2019-2023

Below are some of the key findings from the hemophilia A therapeutics market analysis:

See the complete table of contents and list of exhibits, as well as selected illustrations and example pages from this report.

Get a FREE sample now!  

Global hemophilia A therapeutics industry overview

The increased demand for prophylactic treatment for hemophilia A is one of the critical reasons that will drive the hemophilia A therapeutics market’s growth. This treatment minimizes the risk of developing inhibitors and prevents bleeding episodes. Prophylactic clotting factor regimen not only prevents hemarthrosis that is associated with hemophilia A but also avoids chronic microhemorrhage into joints. Many patients are using long-acting recombinant factor VIII therapies as prophylactic treatments.

The emergence of novel convenient approaches is gaining prominence in the market as they offer long-lasting therapeutic benefits from bleeding episodes. This will drive the hemophilia A therapeutics market to grow at a CAGR of almost 7% during the forecast period. AFSTYLA is one of the best examples of long-lasting therapy that is used to reduce the frequency of bleeding episodes in patients with hemophilia A.

Top hemophilia A therapeutics companies covered in this market research report

The hemophilia A therapeutics market is fairly fragmented. By offering a complete analysis of the market’s competitive landscape and with information on the products offered by the companies, this hemophilia A therapeutics industry analysis report will allow the clients to identify new growth opportunities and design innovative strategies to improve their share in the market.

The report offers a complete analysis of various companies including:

• Bayer
• CSL
• Novo Nordisk
• Pfizer
• Shire

Hemophilia A therapeutics market segmentation based on geographic regions

• Americas
• APAC
• EMEA

The Americas will contribute the highest market share throughout the forecast period.  The new drug approvals of long-acting and curative therapies for hemophilia A is one of the primary reasons for the high growth of the hemophilia A therapeutics market in this region.

Hemophilia A therapeutics market segmentation based on product

• Recombinant therapies
• Plasma-derived therapies
• Hormonal therapies

The recombinant therapies segment will account for the highest market share in the hemophilia A therapeutics market as recombinant therapies that treat hemophilia A are safer than plasma-derived products.

Key highlights of the global hemophilia A therapeutics market for the forecast years 2019-2023:

• CAGR of the market during the forecast period 2019-2023
• Detailed information on factors that will accelerate the growth of the hemophilia A therapeutics market during the next five years
• Precise estimation of the global hemophilia A therapeutics market size and its contribution to the parent market
• Accurate predictions on upcoming trends and changes in consumer behavior
• The growth of the hemophilia A therapeutics industry across various geographies such as the Americas, APAC, and EMEA
• A thorough analysis of the market’s competitive landscape and detailed information on several vendors
• Comprehensive details on factors that will challenge the growth of multivariable transmitters companies

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch